13.77

4.79% 0.63

Maplight Therapeutics Inc (MPLT)

Overview News Price History Discussions Forecast

Maplight Therapeutics Inc stock is traded at $13.77, with a volume of 550.85K. It is up +4.79% in the last 24 hours and up +6.41% over the past month. MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Previous Close:

$13.14

Open:

$13.03

24h Volume:

550.85K

Relative Volume:

0.71

Market Cap:

$638.62M

Revenue:

Net Income/Loss:

$-161.15M

P/E Ratio:

-3.7067

EPS:

-3.7149

Net Cash Flow:

$-138.61M

1W Performance:

+9.29%

1M Performance:

+6.41%

6M Performance:

-23.61%

1Y Performance:

+0.00%

1-Day Range:

$13.00

$14.14

1-Week Range:

$12.12

$14.14

52-Week Range:

$9.10

$40.43

Maplight Therapeutics Inc Stock (MPLT) Company Profile

Name

Maplight Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

650-839-4360

Address

800 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

133

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

MPLT's Discussions on Twitter

Compare MPLT vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MPLT Maplight Therapeutics Inc	13.77	520.82M	0	-161.15M	-138.61M	-3.7149
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-08-26	Initiated	Needham	Buy
Apr-07-26	Initiated	TD Cowen	Buy
Mar-19-26	Initiated	Canaccord Genuity	Buy
Nov-21-25	Initiated	Jefferies	Buy
Nov-21-25	Initiated	Leerink Partners	Outperform
Nov-21-25	Initiated	Morgan Stanley	Overweight
Nov-21-25	Initiated	Stifel	Buy

View All

Maplight Therapeutics Inc Stock (MPLT) Latest News

Aug 21, 2026

Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study - Business Wire

Aug 21, 2026

Blue Owl Capital Holdings LP Takes $26.16 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat

Aug 21, 2026

Aug 20, 2026

MPLT: MapLight Therapeutics, Inc.Financial Overview - Zacks Investment Research

Aug 20, 2026

MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% - Stock Titan

Aug 20, 2026

Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7%Should You Sell? - MarketBeat

Aug 20, 2026

Aug 19, 2026

MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs - Stock Titan

Aug 19, 2026

MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs - Stock Titan

Aug 19, 2026

MapLight (MPLT) Reported Results Review: The EPS Result Is Below Expectation in the Reported Period; Trading-Day Reaction: Shares Rise 5.11% in Latest TradingGuidance Downgrade Alert - Vinanet

Aug 19, 2026

Aug 18, 2026

Catalyst4 builds 49.9% MapLight (MPLT) stake in private share deal - Stock Titan

Aug 18, 2026

Aug 17, 2026